|
|
Marketing Authorisations
|
|
|
|
|
Insufficiently effective, like other antidiarrhoeals
|
|
|
|
|
|
|
|
|
|
A few cases of dysplasia prevented, but an increase in painful reactions
|
|
|
|
|
|
|
|
|
|
Continue to use established regimens
|
|
|
|
|
|
|
|
|
|
Alirocumab: efficacy still not demonstrated for prevention of cardiovascular disease
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
First-choice treatments
|
|
|
|
|
|
|
|
|
|
Fampridine, after a second look: unfavourable harm-benefit balance
|
|
|
|
|
|
|
|
|
|